Anixa Biosciences, Inc. (ANIX) Stock Score, Valuation & Financial Research

Anixa Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ANIX

Anixa Biosciences, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 3.02. These figures are a research snapshot, not a buy or sell recommendation.

What Anixa Biosciences, Inc. does

Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.

Company business and revenue

Research reporting period: 2025-10-31. A research update is not a new financial filing.

How the company makes money

Anixa Biosciences is a biotechnology company that focuses on the development of oncology therapies and vaccines. The company operates as a research and development entity, currently generating no product revenue and relying on capital raises and equity offerings to fund its clinical trials and operations.

Products and services

  • The company is developing a portfolio of oncology-focused assets, including a CAR-T therapy for ovarian cancer (lira-cel) and a breast cancer vaccine, both currently in clinical trial stages.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes various unnamed third-party contract research organizations to manage and conduct its clinical trials. Source

Business relationships and partnerships

  • The Wistar Institute — A research partner and licensor of CAR-T technology used in the company's Certainty subsidiary. Source
  • H. Lee Moffitt Cancer Center and Research Institute, Inc. — A clinical research collaborator involved in the human clinical testing of the company's CAR-T technology. Source

Business strengths to evaluate

  • Strategic collaborations with established research institutions like Wistar and Moffitt. Source

Business risks and research considerations

  • History of operating losses and dependence on external financing to fund operations. Source
  • Uncertainty regarding the success of clinical trials and regulatory approval processes. Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ANIX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.02
Market capitalization:
102.75M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -10.42M
Free cash flow:
USD -7.17M
Cash:
USD 1.4M
Total debt:
USD 174K
EPS:
USD -0.30

What stands out

  • Free cash flow is USD -7.17M, negative for the stored period.
  • The balance sheet shows USD 1.4M of cash versus USD 174K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 1.22M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ANIX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ANIX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ANIX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ANIX to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of ANIX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ANIX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.